ArticleFuture microbiology
Enhancing colistin efficacy with combination therapies for multidrug-resistant
Article in Future microbiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Evolving Clonal, Plasmid-Mediated Resistome, Virulome and Therapeutic Landscape of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Synergistic strategies to rescue the last-resort antibiotic colistin.Archives of microbiology · 2026Review
- Perspectives on Colistin-An Old Antibiotic with Renewed Relevance in Modern Medicine.International journal of molecular sciences · 2026Review
- Antimicrobial resistance and microbiological gap analysis for central nervous system-assocaited bacterial pathogens in Nigeria.Frontiers in microbiology · 2026Article
- The colistin resistance pandemic: A dual threat from plasmid-encoded mobilised colistin resistance genes and chromosomal mutations.African journal of laboratory medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIncreasing resistance among ESKAPEEc pathogens, particularly MATERIALS &
methodsThis study evaluated the in vitro efficacy of colistin in combination with doxycycline, doripenem, and rifampicin against multidrug-resistant clinical isolates of
resultsAll isolates were resistant to colistin, according to their MICs. In checkerboard assays, according to synergism rates, colistin-doripenem and colistin-doxycycline combinations were particularly effective. The degrees of synergy for doripenem, doxycycline, and rifampicin were 30%, 90%, and 20%, respectively, against
conclusionsColistin-based combination therapies, especially colistin-doripenem, may be promising approaches for combating multidrug-resistant pathogens while potentially reducing nephrotoxicity risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.